SCHEMBL5035145

SCHEMBL5035145

Cc1sc(N(C(=O)c2ccc(Cl)cc2Cl)c2ccc(Cl)cc2)nc1C(=O)N1CCC(O)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
ADORA2B P29275 6/20 0.39
KMT2A Q03164 2/20 0.39
CYP3A4 P08684 1/20 0.38
PDE2A O00408 1/20 0.37
RORC P51449 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
ADORA2A P29274 1/20 0.34
PROKR1 Q8TCW9 1/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14217575 1.00 CNR1 (0.46) CNR1CNR2ADORA2BKMT2ACYP3A4
SCHEMBL5034690 0.90 CNR1 (0.40) CNR1CNR2ADORA2BKMT2APDE2A
SCHEMBL5032570 0.90 CNR1 (0.40) CNR1CNR2ADORA2BKMT2APDE2A
SCHEMBL5032576 0.90 CNR1 (0.40) CNR1CNR2ADORA2BKMT2APDE2A
SCHEMBL5035011 0.87 CYP3A4 (0.41) CNR1CNR2KMT2ACYP3A4ALDH1A1
SCHEMBL5035195 0.87 CYP3A4 (0.38) CNR1CNR2ADORA2BKMT2ACYP3A4
SCHEMBL5035192 0.87 CYP3A4 (0.38) CNR1CNR2ADORA2BKMT2ACYP3A4
SCHEMBL5035027 0.85 HTR2C (0.48) CNR1CNR2KMT2ACYP3A4KDM4E
SCHEMBL5032538 0.82 HTR2C (0.42) CNR1CNR2ADORA2BKMT2ACYP3A4
SCHEMBL5032540 0.82 HTR2C (0.42) CNR1CNR2ADORA2BKMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885ADORA2B 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.